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A male patient with profound mental retardation, athetosis, nystagmus, and severe congenital hypotonia (Duchenne
muscular dystrophy [DMD]) was previously shown to carry a pericentric inversion of the X chromosome,
46,Y,inv(X)(p21.2q22.2). His mother carried this inversion on one X allele. The patient’s condition was originally
misdiagnosed as cerebral palsy, and only later was it diagnosed as DMD. Because the DMD gene is located at
Xp21.2, which is one breakpoint of the inv(X), and because its defects are rarely associated with severe mental
retardation, the other clinical features of this patient were deemed likely to be associated with the opposite breakpoint
at Xq22. Our precise molecular-cytogenetic characterization of both breakpoints revealed three catastrophic genetic
events that had probably influenced neuromuscular and cognitive development: deletion of part of the DMD gene
at Xp21.2, duplication of the human proteolipid protein gene (PLP) at Xq22.2, and disruption of a novel gene.
The latter sequence, showing a high degree of homology to the Sec4 gene of yeast, encoded a putative small guanine-
protein, Ras-like GTPase that we have termed “RLGP.” Immunocytochemistry located RLGP at mitochondria. We
speculate that disruption of RLGP was responsible for the patient’s profound mental retardation.
Mental retardation, a common clinical condition, is not
well studied, despite its high cumulative prevalence. X-
linked mental retardation (XLMR) is the most frequent
type of mental deficiency seen in males, with an incidence
of ∼1 in 500–600 boys, although it appears to be
highly heterogeneous (Herbst and Miller 1980; Steven-
son 2000). XLMR conditions are classified as either
syndromic XLMR (MRXS) or nonspecific (or nonsyn-
dromic) XLMR (MRX). In MRXS, mental retardation is
one clinical manifestation within a complex syndrome,
whereas patients with MRX share no distinctive clinical
or biochemical manifestations apart from cognitive im-
pairment (Stevenson 2000; Chelly and Mandel 2001).
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The latest available data concerning XLMR have been
compiled by the European XLMR Study Group and re-
leased on the XLMR Genes Update Web site. In all, 209
families with XLMR (140 with MRXS and 69 with
MRX) have been entered into the database so far, and
118 loci associated with XLMR have been mapped on
the X chromosome. Of those, 34 have yielded specific
genes as causes for mental retardation. Seven genes re-
sponsible for MRX have been cloned; several among
them—PAK3 (p21 activating kinase 3 [MIM 300142]),
OPHN1 (oligophenin-1 [MIM300127]), andARHGEF6
(a guanine nucleotide exchange factor for Rho GTPases
[MIM 00267])—are involved in the Rho-GTPase cycle,
which mediates organization of the cytoskeleton, cell
shape, and motility in neuronal cells (Tonilo 2000;
Chelly and Mandel 2001). In addition, mutations in
GDI1, one of the Rab GDP-dissociation inhibitors that
control recycling of Rab GTPases, have been revealed
in two families with MRX (MRX41 and MRX48)
(D’Adamo et al. 1998).
On the other hand, 27 genes responsible for MRXS
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have been identified. Among them are FGD1 (faciogen-
ital dysplasia protein 1), an activator of Rho GTPase
(Cdc42) (Zheng et al. 1996), and DDP (deafness/dys-
tonia peptide), which shows similarity to yeast mito-
chondrial proteins and plays an important role in the
mitochondrial protein-import system (Jin et al. 1996).
Moreover, a missense mutation in the RSK2 (ribosomal
S6 kinase 2 [MIM 300075]) gene, which was first iden-
tified as the element responsible for Coffin-Lowry syn-
drome, has also been reported in one family (MRX19)
(Trivier et al. 1996). The combined evidence indicates
that genes participating in various stages of intracellular
signaling, especially members of the GTP-binding family,
are likely to play critical roles in the development of
cognitive functions, and impairment of their activities
may result in mental retardation (Tonilo 2000; Chelly
and Mandel 2001).
Recently we detected a constitutional chromosomal
aberration in a 16-year-old male patient with Duchenne-
type muscular dystrophy (DMD [MIM 300377]), an
inv(X) (p21.2q22.2). This patient’s DMD symptoms
were accompanied by profound mental retardation,
athetosis, and nystagmus. Such profound neurological
symptoms are quite rare in DMD; however, loci asso-
ciated with MRXS in 10 families and with MRX in 8
others have been mapped around Xq22-23. We hypoth-
esized that the breakpoints rearranged in this patient’s
inv(X)(p21.2q22.2) might have disrupted not only the
DMD gene but also additional, unidentified gene(s) that
could account for his neurological symptoms.
The patient was the third child of nonconsanguineous
Japanese parents; he was born by spontaneous normal
delivery, with a birth weight of 3,000 g. No history of
neuromuscular anomalies had been described in his fam-
ily. As a newborn, he exhibited less-than-normal move-
ment and activity, as well as weakness in suckling. A
muscle biopsy at age 4 mo indicated that these features
were compatible with muscular dystrophy. His condition
was subsequently diagnosed as congenital muscular dys-
trophy accompanied by mental retardation, congenital
nystagmus, and athetosis. He was never able to speak any
meaningful words or to sit without support.When hewas
15 years old, DMDwas diagnosed by use ofDNAanalysis
that indicated deletion ofDMD exons 43–60. Subsequent
cytogenetic analysis of peripheral lymphocytes re-
vealed karyotypes in the patient and his mother of
46,Y,inv(X)(p21.2q22.2) and 46,X,inv(X)(p21.2q22.2),
respectively. By this time (age 16 years), he was severely
hypotonic, with extreme weakness of the head and neck
muscles, but retained smooth-pursuit eye movements. He
presented rigidity of the spine, scoliosis, and increased
lordosis as well. His mental retardation was too severe
for its actual degree to be assessed. At the age of 18 years,
he died of suffocation due to tracheal obstructionby viscid
sputum. Before the present study, appropriate informed
consent was obtained from the patient’s mother.
Epstein-Barr virus–transformed lymphoblastoid cell
lines (LCLs) were established from peripheral blood lym-
phocytes of the patient, his mother, and normal volun-
teers and were employed in the present study. We first
performed FISH, as described elsewhere (Ariyama et al.
1995; Saito et al. 1995), to investigate the breakpoints
involved in the inv(X). A total of 22 CEPH YACs rep-
resenting the regions of interest at Xp21-p22 (YACs
931B3, 965C6, 808E8, 874A8, 940C10, 779G5, 954F3,
912B8, 939F7, and 821F5) and Xq21-q22 (YACs
768A10, 756A5, 886H6, 896F12, 874B5, 223D3,
883D1, 768E1, 857G9, 962C9, 821C4, and 940G5),
and a BAC clone (RP11-208J19) containing the human
PLP gene were used as probes. Among the 22 YACs
examined, we observed no specific signals for 6 (808E8,
940C10, 939F7, 779G5, 954F3, and 874A8), and the
signals for YACs 912B8 and 965C6 were reduced on
inv(X) chromosomes (fig. 1A) from both the patient and
his mother. However, strong and specific signals of all
eight of those YACs were detected on Xp21 in normal
X chromosomes from the mother and from normal vol-
unteers, indicating that submicroscopic regions of DNA
involved in the inv(X) were deleted between DXS1219
and WI-2651 and that the distal site of the deletion lay
within YAC 965C6. When FISH analysis was performed
using a BAC that contained human PLP sequence, an
extra-copy signal was detected at Xp21 in addition to
a normal copy of PLP on inv(X) in both the patient (fig.
1B) and his mother (data not shown).
PCR amplification was performed with genomic DNA
as a template and with primer-pairs designed to amplify
the STS markers or the additional seven primer-pairs
indicated in figure 1A. (PCR primer sequences and re-
action conditions are available on request from the cor-
responding author.) Amplified products were obtained
at loci between DXS1097 and DXS985, as well as in
DMD exon 41, whereas no PCR products were gener-
ated at loci from DXS726 to WI-9121 or in DMD exon
42 (fig. 1A). These results indicated that the proximal
boundary of the Xp21 deletion of inv(X) lay between
exons 41 and 42 (intron 41) of the DMD gene and that
the telomeric boundary would lie between DXS726 and
DXS1097. Additional PCR analyses, using primer pairs
Pr1–Pr5 (fig. 1) that were prepared according to the
genomic DNA sequence database for this portion of the
X chromosome, yielded products only with primers
Pr1–Pr3. Therefore, the proximal breakpoint at Xp21
in the inv(X) lies between Pr3 and Pr4 (fig. 1A). We
estimated the length of the deletion to be ∼1.3 Mb
(Nataraja et al. 1998).
For further analysis of the Xp21 breakpoint, we per-
formed Southern blot analysis. Genomic DNAs extracted
from LCLs derived from the patient, his mother, and nor-
Figure 1 Results of investigations of Xp21. A, Summarized genomic structure at Xp21 around one breakpoint in the patient with inv(X).
YACs and STSs between markers WI-7235 and WI-5231 were positioned according to information archived in the Whitehead Institute/MIT
Center and Sanger Centre databases. Black, hatched, and white bars indicate YACs that showed no specific signal, reduced signal, or normal
signal, respectively. The presence () or absence (–) of a PCR product from the STS markers is indicated in the third row of the top panel.
The presence () or absence (–) of PCR products is indicated in the third row of the bottom panel. E p EcoRI; H p HindIII; B p BglII. B,
FISH analysis, using a BAC that contains human PLP sequence. In addition to a normal copy of PLP at Xq22, an extra-copy signal was detected
at Xp21 on inv(X) in both the patient and his mother. C, Southern blot analysis, using the Pr3 product as a probe. Lane P, DNA from patient
with inv(X)(p21.2q22.2); lane M, patient’s mother’s DNA; and lane N, normal DNA. Rearranged fragments, which appeared when the DNA
samples of the patient and his mother were digested with HindIII (9.8 kb), HindIII/EcoRI (4.8 kb), or HindIII/BglII (2.6 kb), are indicated by
asterisks (*). D, Genomic sequence spanning the inversion breakpoint. Clone c11T3 was isolated from a cosmid library constructed from DNAs
of the patient’s LCLs.
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mal individuals were digested with HindIII, HindIII plus
EcoRI, or HindIII plus BglII, as described elsewhere (Im-
oto et al. 2001). Southern blotting detected rearranged
bands only when the PCR product from the Pr3 primer
set was used as a probe (fig. 1C), indicating unambigu-
ously that the Xp21 breakpoint lay in the vicinity of the
Pr3-amplified sequence. Next, we constructed and per-
formed screening of a cosmid library from genomic DNA
derived from the patient, as described elsewhere (Inazawa
et al. 1993). Clones containing the DMD (Xp21) break-
point were screened by colony hybridization, using an
[32P]-dCTP–labeled PCR product Pr3 (fig. 1A) as a probe,
and we obtained five clones by screening the cosmid li-
brary of genomic DNAs derived from the patient with
the Pr3 PCR product as the screening probe. When FISH
analysis was performed, using these five clones as probes,
signals for cos11T3 appeared split into two loci (i.e.,
Xp21 and Xq22) on the normal chromosome but were
seen only at Xp22 on the inv(X) (data not shown). There-
fore, cos11T3 was most likely to contain sequence har-
boring the Xq22 breakpoint of the inv(X). Subsequently,
subclonedHindIII/BglII fragments of cos11T3 into pBlue-
script SK plasmid vector (Stratagene) were sequenced us-
ing PRISM 377 ABI autosequencers (Applied Biosystems
Japan); sequences were assembled with the Auto-Assem-
bler program (Applied Biosystems) and were character-
ized using the BLAST program.
By sequencing, we identified two clones (pc1105 and
pc1117) that contained parts of DMD intron 41 and
also a sequence from cosmid U237H1 (Xq22; Gen-
Bank accession number Z95624) that we identified as
a novel ras-like GTPase gene and designated “RLGP.”
On the basis of the genomic database of the U.S. Na-
tional Center for Biotechnology Information, physical
distance between PLP and RLGP genes is ∼836 kb
(GenBank accession number NT_027217). Complete se-
quence analyses of these two plasmids revealed that the
breakpoint at Xq22 lay 143–145 bp upstream from the
putative start codon of RLGP (figs. 1D and 2). The
region surrounding this breakpoint contained sequence
(250 to 120 bp from the putative start codon) that
a computer search (PROSCAN) predicted as a promoter.
The BLAST program predicted that the amino acid
sequence of RLGP protein would contain a GTP-bind-
ing domain similar to RAS small GTPase, as well as
an SOCS (suppressors of cytokine signaling) domain.
The putative gene product showed 99%, 88%, and
72% identities, respectively, to RAR2A (Xq22.1), RAR
(17q25.3), and RAR-like protein (16p13.3), all of which
are human homologues of Saccharomyces cerevisiae
SEC4 proteins (data not shown).
To gain insight into the distribution of RLGPmRNA,
we performed northern blots containing RNA from dif-
ferent human tissues (human 12-laneMTN blots) (Clon-
tech). As shown in figure 3, a single RLGP transcript
was detected in brain, heart, skeletal muscle, kidney, and
liver but was undetectable in seven other tissues, in-
cluding peripheral blood leukocytes. Adjustment of the
signal to that ofGAPDHmRNA indicated that the brain
had the highest level of expression among the 12 tissues
examined. In addition, we confirmed RLGP-specific RT-
PCR product, containing a putative coding region and
5′ as well as 3′ UTR of this gene, could be detected in
human brain tissue (data not shown). However, because
RNA from the patient or his mother was available only
from LCLs established from peripheral lymphocytes and
because RLGP was not expressed in these materials
(data not shown), we were unable to evaluate expression
of this gene in the patient.
To further determine the subcellular localization of
RLGP, we performed indirect fluorescent immunocyto-
chemistry using a pEGFP-RLGP (green) construct (fig.
4). Expression constructs of RLGP were assembled by
cloning the coding sequence of this gene in-frame with
green fluorescent protein (GFP) in the pEGFP-C1 or N1
vector (Clontech), and transfected into COS7 cells, using
Lipofectamine Plus (Invitrogen). Cells fixed with 2%
paraformaldehyde were incubated with mouse mono-
clonal anti–human mitochondria (1:100 dilution;
Chemicon International) or anti-Grp78 (1:200 dilution;
Stressgen Biotechnologies) antibodies. Binding was de-
tected by rhodamine-conjugated anti–mouse IgG (1:
1,000 dilution; Molecular Probes). Fluorescence was ob-
served by means of a confocal laser-scanningmicroscope
(Personal Confocal System, Olympus). The stained RLGP
overlapped with antimitochondrial staining but showed
no specific accumulation in the endoplasmic-reticulum
compartment labeled by anti-Grp78. The staining pat-
terns of both N- and C-terminal–tagged RLGP con-
structs were similar. Nuclear accumulation of green flu-
orescence was occasionally observed in cells transfected
with pEGFP-RLGP (fig. 4). However, since this color
was detected predominantly in the nucleus of cells trans-
fected with pEGFP mock-vector only (data not shown),
the apparent nuclear accumulation may have been non-
specific background due to the proteolytic cleavage of
the GFP-RLGP fusion protein.
Mild mental retardation is a clinical feature in about
one-third of patients with DMD; studies of large cohorts
of patients with DMD have revealed a mean IQ ∼1 SD
below the normal mean (Worden and Vignos 1962; Du-
bowitz 1965). The relationship between mental retar-
dation and specific deletions of the DMD gene has been
studied, with a significant correlation now recognized be-
tween intellectual impairment and macrodeletions of
DNA in the distal part of DMD (Bushby 1995; Bardoni
et al. 2000; Felisari et al. 2000). However, those studies
were conducted only on patients with DMD who had
mild mental retardation. Although very severe mental
retardation is quite rare as a clinical complication of
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Figure 2 Results of investigations of RLGP. A, Genomic structure of the RLGP gene in relation to the breakpoint located in its 5′ region.
B, The nucleotide and deduced amino acid sequences of the RLGP-encoding cDNA. The nucleotide sequence is numbered on the left, and the
deduced amino acid sequence is numbered on the right. The ras-like GTPase domain is boxed, and an SOCS domain is underlined. The amino
acids that are not identical to those in RAR2A are indicated in boldface type, and the amino acids in RAR2A are shown in parentheses.
DMD, a few patients do have severe mental retardation;
this group seems to represent a different entity (i.e., men-
tal retardation–complicated DMD) (Bandoh et al. 1987;
Bushby et al. 1995). So far as we know, very severe
mental retardation has been reported in one patient with
a complete deletion of DMD, including its 5′ and 3′
noncoding regions (Alimsardjono et al. 1995), and in
two unrelated families in which DMD exon 66 was
skipped in transcription (Wibawa et al. 2000). However,
the patient presented here merely showed a common
type of DMD deletion, involving exons 41–79.
Renier et al. (1981) recognized three types of Peli-
zaeus-Merzbacher disease (PMD [MIM 312080]), a men-
tal retardation syndrome. The classic type, with onset in
infancy and death in late adolescence or young adulthood,
is the most common form and is characterized by initial
signs of nystagmus and extrapyramidal effects, including
rolling head movements or head tremor. The second,
“connatal” type shows rapid progression and is fatal in
infancy or childhood; the third, a transitional form, is
intermediate. Duplication of the PLP gene is detected in
60%–70% of patients with PMD (Sistermans et al. 1998;
Inoue et al. 1999), and such patients invariably show the
classic form with a milder phenotype (weaker demyelin-
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Figure 3 Expression of RLGP mRNA in normal human tissues. The same blot was rehybridized with a GAPDH probe, as a control,
for RNA loading and transfer.
ation) than that of patients who carry PLP point muta-
tions (Sistermans et al. 1998; Inoue et al. 1999). Patients
with PLP duplications commonly maintain head control
and can speak in sentences, and some are able to walk
with assistance. FISH analysis in the present patient un-
ambiguously revealed duplication of PLP in the inv(X);
some of his clinical features, such as nystagmus, extra-
pyramidal athetosis, and relatively long course, met the
criteria for the classic type of PMD. Moreover, patholog-
ical findings in brain sections, stained with Kluver-Barrera
and Holzer stains after his death, showed weak demye-
lination in the cerebral white matter, especially in both
temporal lobes (data not shown), an observation that was
compatible with the classic type of PMD involving PLP
duplication (Sistermans et al. 1998; Inoue et al. 1999).
Among our patient’s clinicopathological features, only the
degree of mental retardation was discordant with the clas-
sic type of PMD. We inferred that additional molecular
mechanisms might be implicated in the pathogenesis of
his very severe mental retardation.
We successfully isolated a novel gene, RLGP, from the
inv(X) breakpoint at Xq22.2 in this patient and showed
that the breakpoint disrupted its putative promoter re-
gion. So far, only seven genes have been identified with
mutations in families with MRX, and three of the genes
were isolated from breakpoints of X;autosome translo-
cations (Billuart et al. 1998; Kutsche et al. 2000; Zemni
et al. 2000). Of these seven genes, six (GDI1, OPHN1,
PAK3, RPS6KA3, IL1RAPL, and TM4SF2) have been
shown to participate in various stages of intracellular sig-
naling (Tonilo 2000; Chelly and Mandel 2001). For ex-
ample, GDI1 and OPHN1 regulate Rab and Rho
GTPases involved in vesicle cycling, neurotransmitter re-
lease, cell migration, and neurite outgrowth (Chelly and
Mandel 2001). PAK3 is a downstream effector of Rho
GTPases (Rac and Cdc42), carrying signals to the actin
cytoskeleton (Sells et al. 1997) andmediatingMAP kinase
cascades, including JNK1 and p38 (Bagrodia et al. 1995).
These circumstances strongly support our view that in-
terruption of RLGP expression might have affected cog-
nitive development in the subject of the present study.
Immunostaining of RLGP protein in cells, by use of
expression constructs tagged with GFP, clearly demon-
strated colocalization of RLGP with mitochondria. A
high-affinity GDP/GTP-binding site is present on mito-
chondrial ribosomes, which may mediate protein synthe-
sis by regulating the initiation complex (Denslow et al.
1991). Moreover, several GTP-binding proteins, mainly
small G proteins, have been identified at points of contact
between the inner and outer mitochondrial membranes
(Thomson et al. 1998; Sleer and Hall 2000). RLGP pro-
tein may work in a similar manner. Moreover, many dis-
eases resulting from defects in mitochondrial DNA in-
volve neurological symptoms. Nuclear genetic disorders
such as Friedreich ataxia (FRDA [MIM 229300]),Wilson
disease (WND [MIM 277900]), and autosomal hered-
itary spastic paraplegia (SPG7 [ MIM 602783]) also in-
volve mitochondrial dysfunction as a direct or indirect
cause of their neurological degenerative phenotypes
(Chinnery et al. 1999). Taking these observations to-
gether, we consider it possible that RLGP may play a
critical role in the development or function of the CNS,
by transducing signals or transporting molecules across
mitochondrial membranes.
In keeping with the marked progression of the Human
Genome Project, numerous genes associated with MRX
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Figure 4 Subcellular localization of RLGP. COS7 cells were transiently transfected with pEGFP-RLGP (A and D), fixed, and immuno-
cytochemically stained using mouse monoclonal anti-human mitochondria (B) or anti-Grp78 (E) antibodies. Note that the localization of RLGP
overlapped with antimitochondrial staining (C) but showed no specific accumulation in the endoplasmic-reticulum compartment labeled by
anti-Grp78 (F).
and/or MRXS have been identified to date. Here, we have
shown that a Ras-like GTPase gene,RLGP,was disrupted
by the inv(X)(Xp21.2;q22.2) in a patient with very severe
mental retardation, although the actual function of this
gene remains unclear. To understand the role that RLGP
might have played in intellectual development of the pa-
tient, as well as in his other clinical features, we acknowl-
edge a need to conduct further clinicopathological char-
acterizations of RLGP, including mutational screening of
this gene in a large group of patients with XLMR. It
should be borne in mind that genes associated with at
least six MRXSs and eight MRXs have been mapped on
Xq22-23 but remain unidentified.
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